Cell Free Tumor DNA to Monitor Response to Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

被引：0

作者：

Ulivi, Paola ^{[1
]}

Chiadini, Elisa ^{[1
]}

Marisi, Giorgia ^{[1
]}

Ludovini, Vienna ^{[2
]}

De Luigi, Nicoletta ^{[3
]}

Dazzi, Claudio ^{[4
]}

Mariotti, Marita ^{[3
]}

Crino, Lucio ^{[2
]}

Delmonte, Angelo ^{[3
]}

机构：

[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biosci Lab, Meldola, Italy

[2] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Perugia, Italy

[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Med Oncol, Meldola, Italy

[4] S Maria Croci Hosp, Med Oncol, Ravenna, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

EGFR T790M; free DNA; TKI; Resistance;

D O I：

10.1016/j.jtho.2016.11.1702

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b035

引用

页码：S1208 / S1208

页数：1

共 50 条

[1] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Fukihara, Jun
Watanabe, Naohiro
Taniguchi, Hiroyuki
Kondoh, Yasuhiro
Kimura, Tomoki
Kataoka, Kensuke
Matsuda, Toshiaki
Yokoyama, Toshiki
Hasegawa, Yoshinori
ONCOLOGY, 2014, 86 (02) : 86 - 93
[2] Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
Kim, Soomin
Koh, Jaemoon
Kim, Tae Min
Oh, Songji
Kim, Soyeon
Youk, Jeonghwan
Kim, Miso
Keam, Bhumsuk
Jeon, Yoon Kyung
Kim, Dong-Wan
Heo, Dae Seog
ISCIENCE, 2025, 28 (02)
[3] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
Dogan, Izzet
Khanmammadov, Nijat
Yildiz, Anil
Ahmed, Melin Aydan
Vatansever, Sezai
Saip, Pinar
Aydiner, Adnan
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
[4] Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC)
Henick, Brian S.
Goldberg, Sarah B.
Narayan, Azeet
Rossi, Chiara
Rodney, Simon
Kole, Adam J.
Politi, Katerina A.
Gettinger, Scott N.
Herbst, Roy S.
Patel, Abhijit
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Aydiner, Adnan
Dogan, Izzet
Khanmammadov, Nijat
Saip, Pinar
Vatansever, Sezai
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] The BIM Deletion Polymorphism in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee, Ji Yun
Ku, Bo Mi
Lim, Sung Hee
Kim, Haesu
Yoo, Kwai Han
Jung, Ki Sun
Song, Haa-Na
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S580 - S580
[7] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
Jassem, Jacek
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
[8] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Rachiglio, Anna Maria
Fenizia, Francesca
Piccirillo, Maria Carmela
Galetta, Domenico
Crino, Lucio
Vincenzi, Bruno
Barletta, Emiddio
Pinto, Carmine
Ferrau, Francesco
Lambiase, Matilde
Montanino, Agnese
Roma, Cristin
Ludovini, Vienna
Montagna, Elisabetta Sara
De Luca, Antonella
Rocco, Gaetano
Botti, Gerardo
Perrone, Francesco
Morabito, Alessandro
Normanno, Nicola
CANCERS, 2019, 11 (03):
[9] Targeting CD24 Enhances the Response to ThirdGeneration Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer
Liang, J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S79 - S79
[10] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
Johnson, Melissa
Garassino, Marina Chiara
Mok, Tony
Mitsudomi, Tetsuya
LUNG CANCER, 2022, 170 : 41 - 51

← 1 2 3 4 5 →